Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 90 Day Period & 180 Day Period

<< Previous

Bullboard Posts

Next >>

Comment by floatinketuckyon Jan 24, 2022 4:48am

549 Views

Post# 34351236

RE:RE:90 Day Period & 180 Day Period

When the PI treated patients in the phase one study they were cured of cancer 67% CR. On That rate they halted the study for the starting of the phase two study. The FDA will never be able un hear the bell that rang during that study.

67% CR with ONE TREATMENT! Say can we dial that back 30 pecent and still hit the bullseye?? PI says to himself...
Hey lets dry run the first patients of study two may also have served nicely for new doctors exucuting their first ever procedure FOR HEALING CANCER AT THE SPEED OF LIGHT?

Principal investigators were concerned for over treating patients! What if they could get the same data points at a 30 percent reduction of the drug used. They have those data points to consider now. If patients are cured with less drug being used the FDA is not going to be sad. If fact they might say TLTFF YOUR MY LITTLE DARLING!!!! Darling Darlin Darlin you got the love I need.....

tdon1229 wrote:

99942Apophis wrote: Newsletter dated November 29 had patients 25 to 30 being treated from the previous Newsletter dated August 30/2021 a time-frame of 3 months. A reasonable assumption would be 2 patients treated per month.
We are now approaching the end of January/2022 which of course is 2 months since the last Newsletter or 4 of the 6 ( patients 25, 26, 27 & 28 ) that were announced treated should have hit that 90 point.
The 90 day end point I believe is plus or minus 7 days!

Looking at the 180 Day we had in the Newsletter of August 30/2021 patients 21 to 24 treated from the previous Newsletter dated June11/2021. That gives us 2 months 3 weeks, lets just say 1 patient for June and 1 for July with 2 for August. That would now put patients 21 & 22 hitting their 180 point at the end of January/2022.

End of February to first week of March in my opinion is Newsletter territory, however news of material substance could be released at any time.

Can't see them being allowed to count any of the first 12 patients treated because of the gross under treatments they received. The only ones they can count are those correctly treated twice as specified for the clinical trial. All others are merely talking points and additional information, not properly treated Phase II trial subjects. Same for the information about the long term results for the two surviving Phase I trial subjects, nice to know, but don't count formally for anything in Phase II.
i awouldn't hold my breath expecting a BTD submittal until they have 20-25 legitimate Ph II trial subject results for 90 & 180 days.